The role of splicing factor mutations in the pathogenesis of the myelodysplastic syndromes.
暂无分享,去创建一个
[1] M. Stratton,et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes. , 2013, Blood.
[2] G. Mufti,et al. Recent advances in understanding the molecular pathogenesis of myelodysplastic syndromes , 2013, British journal of haematology.
[3] J. Maciejewski,et al. Patterns of missplicing due to somatic U2AF1 mutations in myeloid neoplasms. , 2013, Blood.
[4] P. Greenberg. The multifaceted nature of myelodysplastic syndromes: clinical, molecular, and biological prognostic features. , 2013, Journal of the National Comprehensive Cancer Network : JNCCN.
[5] G. Mufti,et al. Spliceosome mutations exhibit specific associations with epigenetic modifiers and proto-oncogenes mutated in myelodysplastic syndrome , 2013, Haematologica.
[6] Benjamin L Ebert,et al. Molecular pathophysiology of myelodysplastic syndromes. , 2013, Annual review of pathology.
[7] A. Raza,et al. The genetic basis of phenotypic heterogeneity in myelodysplastic syndromes , 2012, Nature Reviews Cancer.
[8] A. Jankowska,et al. SF3B1 haploinsufficiency leads to formation of ring sideroblasts in myelodysplastic syndromes. , 2012, Blood.
[9] Seishi Ogawa,et al. Splicing factor mutations in myelodysplasia , 2012, International Journal of Hematology.
[10] D. Neuberg,et al. Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] Iannis Aifantis,et al. ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression. , 2012, Cancer cell.
[12] J. Maciejewski,et al. Emerging roles of the spliceosomal machinery in myelodysplastic syndromes and other hematological disorders , 2012, Leukemia.
[13] M. Gönen,et al. Genetic analysis of patients with leukemic transformation of myeloproliferative neoplasms shows recurrent SRSF2 mutations that are associated with adverse outcome. , 2012, Blood.
[14] Aaron A Hoskins,et al. The spliceosome: a flexible, reversible macromolecular machine. , 2012, Trends in biochemical sciences.
[15] Michael Heuser,et al. Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes. , 2012, Blood.
[16] A. Jankowska,et al. Mutations in the spliceosome machinery, a novel and ubiquitous pathway in leukemogenesis. , 2012, Blood.
[17] Claude Preudhomme,et al. Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes. , 2012, Blood.
[18] E. Giné,et al. Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia , 2011, Nature Genetics.
[19] M. Walter,et al. Genetics of myelodysplastic syndromes: new insights. , 2011, Hematology. American Society of Hematology. Education Program.
[20] Li Ding,et al. RECURRENT MUTATIONS IN THE U2AF1 SPLICING FACTOR IN MYELODYSPLASTIC SYNDROMES , 2011, Nature Genetics.
[21] O. Abdel-Wahab,et al. The spliceosome as an indicted conspirator in myeloid malignancies. , 2011, Cancer cell.
[22] Peter J Campbell,et al. Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms , 2011, Blood.
[23] M. Stratton,et al. Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. , 2011, The New England journal of medicine.
[24] S. Sugano,et al. Frequent pathway mutations of splicing machinery in myelodysplasia , 2011, Nature.
[25] R. Levine,et al. Molecular biology of myelodysplastic syndromes. , 2011, Seminars in oncology.
[26] J. Valcárcel,et al. Reduced fidelity of branch point recognition and alternative splicing induced by the anti-tumor drug spliceostatin A. , 2011, Genes & development.
[27] Benjamin L Ebert,et al. Unraveling the molecular pathophysiology of myelodysplastic syndromes. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] E. Brambilla,et al. Acetylation and phosphorylation of SRSF2 control cell fate decision in response to cisplatin , 2011, The EMBO journal.
[29] Miaosheng Li,et al. Structural requirements for the antiproliferative activity of pre-mRNA splicing inhibitor FR901464. , 2011, Chemistry.
[30] A. McKenzie,et al. Advances in the 5q- syndrome. , 2010, Blood.
[31] John R Yates,et al. Release of SF3 from the intron branchpoint activates the first step of pre-mRNA splicing. , 2010, RNA.
[32] B. Frey,et al. Deep surveying of alternative splicing complexity in the human transcriptome by high-throughput sequencing , 2008, Nature Genetics.
[33] T. Golub,et al. Identification of RPS14 as a 5q- syndrome gene by RNA interference screen , 2007, Nature.
[34] B. Sander,et al. Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q− syndrome patients , 2007, Proceedings of the National Academy of Sciences.
[35] Xiang-Dong Fu,et al. Splicing Regulator SC35 Is Essential for Genomic Stability and Cell Proliferation during Mammalian Organogenesis , 2007, Molecular and Cellular Biology.
[36] M. Minden,et al. Myelodysplastic syndromes: the complexity of stem-cell diseases , 2007, Nature Reviews Cancer.
[37] P. Greenberg,et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. , 2006, The New England journal of medicine.
[38] L. Maquat. Nonsense-mediated mRNA decay: splicing, translation and mRNP dynamics , 2004, Nature Reviews Molecular Cell Biology.
[39] J. Boultwood,et al. Activation of the mTOR pathway by the amino acid (L)-leucine in the 5q- syndrome and other ribosomopathies. , 2013, Advances in biological regulation.
[40] P. Potter,et al. The development and application of small molecule modulators of SF3b as therapeutic agents for cancer. , 2013, Drug discovery today.
[41] G. Garcia-Manero,et al. SF3B1 mutations are prevalent in myelodysplastic syndromes with ring sideroblasts but do not hold independent prognostic value. , 2012, Blood.
[42] A. MacMillan,et al. Structural model of the p14/SF3b155 · branch duplex complex. , 2011, RNA.